Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

Clinical and Translational Oncology

Volumn 15, Issue 4, 2013, Pages 321-326

  Gómez Millán, Jaime ^a   Toledo, Maria Dolores ^a   Lupiañez, Yolanda ^a   Rueda, Antonio ^b   Trigo, Jose Manuel ^a   Sachetti, Antonio ^c   Medina, Jose Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c CROASA Centro Radio Oncológico Andaluz   (Spain)

Author keywords

Accelerated radiation; Concomitant boost radiation; Head and neck cancer; Late toxicity

Indexed keywords

CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; CONCOMITANT BOOST RADIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS DISEASE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LARYNX DISORDER; LIVER DYSFUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SEPSIS; SEPTIC SHOCK; SKIN TOXICITY; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT;

EID: 84876492029     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0925-9     Document Type: Article

References (22)

1. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98
2. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949-955
3. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4-14)
4. Corvo R (2007) Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85:156-170
5. Bernier J, Horiot JC (2012) Altered fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol 24:1-6
6. Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK (2011) Population-based study of competing mortality in head and neck cancer. J Clin Oncol 29(26):3503-3509
7. Medina JA, Rueda A, Sachetti A (2006) A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 79:34-38
8. Fu KK, Pajack TF, Trotti A et al (2000) A radiation therapy oncology group phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 2003. Int J Radiat Oncol Biol Phys 48:7-16
9. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
10. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346
11. Kim J, Tannock I (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5:516-525
12. Bourhis J, Overgaard J, Audry H, Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843-854
13. Ang K, Zhang Q, Wheeler RH et al (2010) A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome [Abstract]. J Clin Oncol 28(Suppl 15):A-5507
14. Bourhis J, Sire C, Lapeyre M et al (2008) Accelerated versus conventional radiotherapy with concomitant chemotherapy in locally advanced head and neck carcinomas: results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 72:S31-S32
15. Blanchard P, Catherine H, Guihenneuc-Jouyaux C (2011) Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 64:985-992
16. Veldeman L, Madani I, Hulstaert F, De Meerleer G et al (2008) Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 9:367-375
17. Allen AM, Elshaikh M, Worden FP et al (2007) Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer. Head Neck 29:137-142
18. Ang KK, Harris J, Garden AS et al (2005) Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 23:3008-3015
19. Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533-4540
20. Argiris A, Brockstein B, Haraf DJ et al (2004) Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10(15):1956-1962
21. Corry J, Peters LJ, Rischin D (2010) Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 11:287-291
22. Rose B, Jong-Hyeon J, Nathe SK (2011) Population based study of competing mortality in head and neck cancer. J Clin Oncol 29(26):3503-3509